Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xenon ( (XENE) ) just unveiled an update.
Xenon Pharmaceuticals reported positive topline results from its Phase 3 X-TOLE2 trial of azetukalner in adults with focal onset seizures, with both 25 mg and 15 mg doses achieving statistically significant reductions in monthly seizure frequency versus placebo. The 25 mg dose delivered a 53.2% median reduction in seizures and a placebo-adjusted effect of 42.7%, surpassing efficacy seen in the earlier Phase 2b X-TOLE study, while maintaining a safety and tolerability profile consistent with prior trials.
The company plans to file a New Drug Application with the U.S. Food and Drug Administration in the third quarter of 2026 for azetukalner as an adjunctive therapy in focal onset seizures, positioning it to become the first KV7 potassium channel opener approved for epilepsy. If approved, azetukalner’s differentiated mechanism, once-daily dosing, lack of titration requirement and minimal drug–drug interactions could strengthen Xenon’s competitive standing in the crowded epilepsy market and offer a new option for patients with highly treatment-resistant disease.
The most recent analyst rating on (XENE) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Xenon stock, see the XENE Stock Forecast page.
Spark’s Take on XENE Stock
According to Spark, TipRanks’ AI Analyst, XENE is a Neutral.
The score is driven by a strong balance sheet and positive earnings-call outlook with clear Phase III milestones and stated runway into 2027. These positives are tempered by very weak operating financials (large losses and accelerating cash burn) and only moderate valuation support due to negative earnings, while technicals are favorable but somewhat stretched.
To see Spark’s full report on XENE stock, click here.
More about Xenon
Xenon Pharmaceuticals Inc., based in Vancouver and Boston, is a neuroscience-focused biopharmaceutical company specializing in the discovery, clinical development and commercialization of therapeutics for patients with neurological disorders. Its lead programs include azetukalner, a novel KV7 potassium channel opener being developed for epilepsy and depression, with a particular focus on treatment-resistant focal onset seizures.
Average Trading Volume: 916,820
Technical Sentiment Signal: Strong Buy
Current Market Cap: $3.49B
See more insights into XENE stock on TipRanks’ Stock Analysis page.
